Messenger RNA medicines company Arcturus Therapeutics Holdings Inc (Nasdaq:ARCT) announced on Thursday that it has entered into a strategic collaboration with Thermo Fisher Scientific Inc (NYSE:TMO) to support Phase 3 development and potential commercialisation of ARCT-032, an investigational mRNA therapy for cystic fibrosis.
The agreement focuses on advancing clinical and manufacturing capabilities for the programme.
The collaboration will leverage Thermo Fisher's Accelerator Drug Development platform, integrating manufacturing, clinical research, and commercial readiness services. Thermo Fisher will support Phase 3 manufacturing and clinical research activities through its PPD clinical research business, subject to positive Phase 2 results.
If ARCT-032 receives regulatory approval, Thermo Fisher will obtain exclusive commercial manufacturing rights under a separate agreement. The arrangement is designed to support development continuity from late-stage clinical trials through potential market launch.
Insmed's BRINSUPRI (brensocatib) non-cystic fibrosis bronchiectasis treatment approved by US FDA
Fosun Pharma agrees XH-S004 overseas licensing deal
Itepekimab meets primary endpoint in one of two Phase 3 COPD trials
Inogen secures FDA clearance for SIMEOX 200 Airway Clearance Device
Infex Therapeutics begins Phase IIa trial for RESP-X in NCFB patients
SalioGen Therapeutics names new chief medical officer
Destiny Pharma launches research on XF-73 for cystic fibrosis MRSA infections
Polarean Imaging enters into trade-in agreement with University of Kansas Medical Center
Sionna Therapeutics doses first healthy subject in SION-109 phase one clinical trial
Arcturus Therapeutics granted FDA Orphan Drug Designation for ARCT-032 to treat cystic fibrosis
SpliSense completes SPL84 first-in-human, Phase one clinical trial for cystic fibrosis treatment
Positive Phase 2, Proof-of-Concept Results for VX-548 Published in New England Journal of Medicine